Less Ads, More Data, More Tools Register for FREE

Pin to quick picksTate & Lyle Regulatory News (TATE)

Share Price Information for Tate & Lyle (TATE)

Share Price is delayed by 15 minutes
Get Live Data
491.40    -13.10 (-2.60%)
Bid:
498.00
Ask:
500.00
Spread: 2.00 (0.402%)
Market Cap: £2.17b
TATE Live PriceLast checked at - London Stock Exchange

Intraday Tate & Lyle Share Chart

Director/PDMR Shareholding

7 Dec 2020 11:06

RNS Number : 7678H
Tate & Lyle PLC
07 December 2020
 

Tate & Lyle PLC

Notification of transaction by Persons Discharging Managerial Responsibilities

Tate & Lyle PLC (the 'Company') announces that a grant of nil-cost options over the Company's ordinary shares of 25 pence each in the capital of the Company ('Shares') was made on 3 December 2020 under the Tate & Lyle Performance Share Plan 2020 ('PSP') to the Person Discharging Managerial Responsibilities ('PDMR') detailed in the table below:

PDMR

No. of Shares subject to award

Victoria Spadaro Grant

160,278

Awards granted under the PSP will only vest to the extent that certain performance criteria are satisfied by the Company over a three-year performance period which runs from 1 April 2020 to 31 March 2023. These criteria are described in the Annual Report 2020. No consideration is payable for the grant or exercise of the options.

 

The notification below, which has been made in accordance with the requirements of the EU Market Abuse Regulation, provides further detail.

 

Claire-Marie O'Grady

Company Secretary

7 December 2020

 

 

 

 

 

 

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them

 

 

Details of PDMR / person closely associated with them ("PCA")

a)

Name

Victoria Spadaro Grant

2.

Reason for the notification

a)

Position / status

PDMR

b)

Initial notification / amendment

Initial notification

3.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Tate & Lyle PLC

b)

LEI

2138008K14474WPKZ244

4.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument

Identification code

Ordinary shares of 25 pence each in the capital of Tate & Lyle PLC

 

GB0008754136

b)

Nature of the transaction

Grant of nil-cost awards over shares for no consideration under the Tate & Lyle Performance Share Plan 2020

c)

Price(s) and volume(s)

Price(s)

Volume(s)

Nil

160,278

 

d)

Aggregated information

- Aggregated volume

- Price

 

 

160,278

 

Nil

e)

Date of the transaction

2020-12-03

f)

Place of the transaction

Outside a trading venue

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
DSHUBRARRVUURAA
Date   Source Headline
7th Aug 202312:15 pmRNSDirector/PDMR Shareholding
3rd Aug 20233:45 pmRNSDirector/PDMR Shareholding
2nd Aug 202311:30 amRNSHolding(s) in Company
1st Aug 202311:15 amRNSTotal Voting Rights
28th Jul 202312:00 pmRNSDirector/PDMR Shareholding
27th Jul 20231:15 pmRNSResult of AGM
27th Jul 20239:30 amRNSHolding(s) in Company
26th Jul 202311:30 amRNSHolding(s) in Company
25th Jul 202311:30 amRNSHolding(s) in Company
24th Jul 202312:30 pmRNSHolding(s) in Company
18th Jul 202312:30 pmRNSHolding(s) in Company
4th Jul 20233:00 pmRNSDirector/PDMR Shareholding
3rd Jul 20232:10 pmRNSBlock listing Interim Review
3rd Jul 20232:00 pmRNSTotal Voting Rights
3rd Jul 20237:02 amRNSDirectorate Change
29th Jun 20233:30 pmRNSHolding(s) in Company
28th Jun 20232:00 pmRNSHolding(s) in Company
7th Jun 20232:30 pmRNSDirector/PDMR Shareholding
6th Jun 202312:30 pmRNSAnnual Financial Report and Notice of AGM 2023
1st Jun 202312:00 pmRNSTotal Voting Rights
25th May 20237:00 amRNSFinal Results
18th May 20239:30 amRNSDirector Declaration
2nd May 20232:30 pmRNSTotal Voting Rights
4th Apr 202311:00 amRNSOperating Segment Restatement
3rd Apr 20234:15 pmRNSTotal Voting Rights
8th Mar 20232:30 pmRNSDirector/PDMR Shareholding
8th Feb 20237:00 amRNSCapital Markets Event
26th Jan 20237:00 amRNSTrading Statement
6th Jan 20232:00 pmRNSDirector/PDMR Shareholding
3rd Jan 20233:17 pmRNSBlock listing Interim Review
8th Dec 20221:00 pmRNSDirector/PDMR Shareholding
30th Nov 20222:00 pmRNSHolding(s) in Company
10th Nov 20227:00 amRNSHalf-year Report
1st Nov 20223:15 pmRNSTotal Voting Rights
4th Oct 20228:25 amRNSCancellation of Preference Share Listing
3rd Oct 20222:45 pmRNSPref. share reduction effective & timetable update
29th Sep 20221:00 pmRNSTimetable update re. cancellation of pref. shares
14th Sep 202212:15 pmRNSHolding(s) in Company
13th Sep 20223:00 pmRNSCourt approval of cancellation of Pref. shares
10th Aug 20222:15 pmRNSDirector/PDMR Shareholding
4th Aug 20223:00 pmRNSDirector/PDMR Shareholding
2nd Aug 20224:00 pmRNSHolding(s) in Company
28th Jul 20221:00 pmRNSUpdate on Preference Share Reduction Timetable
28th Jul 202212:45 pmRNSResult of AGM
15th Jul 20225:20 pmRNSDirector/PDMR Shareholding
1st Jul 202210:45 amRNSBlock listing Interim Review
1st Jul 202210:17 amRNSTotal Voting Rights
29th Jun 20224:25 pmRNSDirector/PDMR Shareholding
29th Jun 20224:00 pmRNSDirector/PDMR Shareholding
24th Jun 20224:15 pmRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.